Clinical trial
Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With…
NCT00071955 · Genitope Corporation, Industry · Completed
Key facts
| NCT number | NCT00071955 |
|---|---|
| Title | Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study to Evaluate Safety and Efficacy of Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH and GM-CSF Following the Anti-CD20 Antibody, Rituximab, in Previously Treated Patients With Follicular Non-Hodgkin's Lymphoma |
| Lead sponsor | Genitope Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim |
| Start date | Mar 1, 2003 |
| Completion | Jan 1, 2009 |
| First posted | Nov 6, 2003 |
| Last update posted | Dec 19, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: